In conclusion, our findings indicate a substantial discordance of EGFR and K-RAS mutations between the primary tumours and the corresponding metastases in NSCLC and underline the need to consider the genotype of both primary and metastatic tumours for selecting patients who will respond to therapy with TKIs. This evidence concerns the gene KRAS and neoplasm.